What's Next for Dynavax?

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

Dynavax Technologies (NASDAQ: DVAX  )  is down more than 30% in early trading today following a Food and Drug Administration rejection for its hepatitis B vaccine Heplisav. The FDA cited safety and manufacturing concerns but indicated a willingness to consider a more limited approval. What's next for Dynavax's lead drug candidate?

Rejection recalibration
Hepatitis B is an infectious disease that affects the liver. Acute patients may show few symptoms, but chronic cases can lead to cirrhosis and other potentially fatal conditions.

Heplisav was closely watched last year because it presented similar efficacy as GlaxoSmithKline's (NYSE: GSK  ) Engerix-B, but offered vast dosage improvement. Glaxo's drug includes up to four doses given over the span of six months; Dynavax's drug has two doses given in one month. The approval of Heplisav may significantly increase the lackluster rates of vaccine adherence.

But that time hasn't come... yet.

Heplisav's complete response letter from the FDA wasn't shocking. An advisory panel last fall voted against the drug's safety but in favor of efficacy. The panel's main problems were the lack of diversity in trial participants and the fact that the drug includes a novel adjuvant. Vaccines often include adjuvants, which improve the chances of an immune response, but the panel noted that Heplisav's might pose severe autoimmune risks.

The FDA's willingness to talk about a restricted approval indicates that Heplisav still has a shot at getting to market for at-risk patients, such as older patients with diabetes since the risks of hepatitis B could outweigh the possible side effects of the drug. A narrow approval would beat no approval, but Dynavax will need to seek broader indications further down the line.

What now?
Heplisav remains under review in the EU for the general adult population and those with chronic kidney disease -- a common comorbidity for hepatitis B.

Dynavax should meet with the FDA within the next six weeks to discuss Heplisav's future. If the company wants approval, it will take the narrower treatment population. But Dynavax should simultaneously circle back for further trials that include a more diverse population and better safety data.

While you can certainly try to make huge gains in biotechs like Dynavax, the best investing approach is to choose great companies and stick with them for the long term. The Motley Fool's free report "3 Stocks That Will Help You Retire Rich" names stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.

Read/Post Comments (0) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2275692, ~/Articles/ArticleHandler.aspx, 9/24/2016 11:57:04 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 1 day ago Sponsored by:
DOW 18,261.45 -131.01 -0.71%
S&P 500 2,164.69 -12.49 -0.57%
NASD 5,305.75 -33.78 -0.63%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/23/2016 4:00 PM
DVAX $11.41 Down -0.21 -1.81%
Dynavax Technologi… CAPS Rating: ***
GSK $43.42 Down -0.16 -0.37%
GlaxoSmithKline CAPS Rating: ***